主题：疫苗战争（1） -- 狂草舞茅

共同点就是mRNA生成蛋白质，刺激免疫系统生成抗体。

不同点，mRNA首尾有cap，比较稳定，不能自我复制。据说进入体内后一个星期即使不分解，也不再制造蛋白质了。

SaRNA会自我复制下去，复制出来的SaRNA会生成蛋白质。至于复制过程和生成蛋白质过程是否有变异，就不知道了。

saRNA有点类似lnp包裹的人造活病毒

国内残留30%以上不愿意打疫苗的人……

而打过疫苗只防重症不妨感染吧

技术上最大的难度，1）找准合适的靶点，合成对应的蛋白质，2）怎么用LNP/LPP之类的技术，把mRNA安全稳定地送入细胞内部。

现在mRNA生产有几个瓶颈

1. Plasmid DNA：DNA模板是最大的瓶颈。因为原来的基因疗法产能根本不可能满足现在疫苗的生产量。

Moderna外包给 Aldevron，后者最近被管理层卖掉了，成交价高达96亿美元现金。

辉瑞美国自产部分，BNT在欧洲向AGC（德国公司）和Biomay (奥地利公司）。

2. LNP

辉瑞BNT向英国Croda购买，Moderna向CordenPharma购买。

3. 生产mRNA疫苗

Moderna外包给Lonza等CDMO.

辉瑞在美国用自有产能生产。

BNT 买了一个位于Marburg, Germany的生产基地，自己生产。

另外还要一些CDMO，多数是老药企的生产基地。bnt在上海和复星合作了一个十亿剂年产能基地，但plasmid DNA及LNP要外购。

AstraZeneca welcomes Court ruling on supply of its COVID-19 vaccine to Europe

FRE, JUN 18, 2021 14:01 CET

AstraZeneca today welcomed the ruling by the Court of First Instance in Brussels. The European Commission had requested 120 million vaccine doses cumulatively by the end of June 2021, and a total of 300 million doses by the end of September 2021. The judge ordered delivery of 80.2 million doses by 27 September 2021. To date, the Company has supplied more than 70 million doses to the European Union and will substantially exceed 80.2 million doses by the end of June 2021. All other measures sought by the European Commission have been dismissed, and in particular the Court found that the European Commission has no exclusivity or right of priority over all other contracting parties.

The judgement also acknowledged that the difficulties experienced by AstraZeneca in this unprecedented situation had a substantial impact on the delay. AstraZeneca now looks forward to renewed collaboration with the European Commission to help combat the pandemic in Europe. The Company remains committed to broad and equitable distribution of the vaccine as laid out in the Advanced Purchase Agreement of August 2020.

In fewer than twelve months, AstraZeneca has worked extremely hard to develop an effective vaccine at no profit and is the second-largest supplier to the EU’s 27 member states.

The supply of the vaccine is estimated to have helped save tens of thousands of lives and to have significantly reduced hospitalisations.1,2 Real World Evidence has consistently shown a greater than 90% reduction in severe disease and hospitalisations caused by COVID-19,3-6 while recent data from England and Scotland demonstrated 92% vaccine effectiveness against hospitalisation from the Delta (previously called “Indian”) variant.5,6

Jeffrey Pott, General Counsel, said: “We are pleased with the Court’s order. AstraZeneca has fully complied with its agreement with the European Commission and we will continue to focus on the urgent task of supplying an effective vaccine, which we are delivering at no profit to help protect people in Europe and around the world from the deadliest pandemic in a generation.”

The Company continues to engage with governments, international organisations and collaborators around the world to ensure broad and equitable access to this well-tolerated and effective vaccine at no profit during the pandemic period.

Vaxzevria

Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

6月15日起開放日本捐贈近124萬劑AZ疫苗施打，23日進入施打疫苗第9天，全台傳出134人接種AZ疫苗後猝死。

对比一下台湾与英美香港地区Adverse Event-Death.

美国：接种3.1亿剂疫苗，5343例接种后猝死，比例十万分之1.72.

英国：截至2021年6月9日共接种：

辉瑞BNT：1560万第一剂+1080第二剂，死亡421，比例：十万分之1.59

AZ：2460万第一剂+1770万第二剂，死亡885，比例：十万分之2.09

Moderna: 56万第一剂，死亡4例，比例：十万分之0.71

注：1. 辉瑞和Moderna优先接种39以下年轻人，AZ优先接种长者。

2. Moderna第二针反应较大，上述第一针比例不反应全貌

香港特别行政区：截至2021年5月30日

科兴：101.5万剂，死亡13例，比例：十万分之1.29

辉瑞BNT：135万剂，死亡8例，比例：十万分之0.59

注：1. 科兴因较安全，优先接种香港65岁以上年长者；

2. 香港预定了750万剂AZ但因为不安全，取消了AZ订单。

台湾省：

日本捐赠的124萬劑AZ疫苗优先接种长者,到目前施打了约100万剂，9天已造成134人猝死，比例十万分之13.4。是英国AZ（优先施打年长者，死亡比例十万分之2.09）的641%，英国辉瑞（十万分之1.59）的843%。

科兴同样优先接种香港年长者。但日本赠台AZ死亡率是香港科兴（十万分之1.29）的1039%。

结论：

日本赠台的这124万剂AZ显然不是正常的AZ，极度危险。年长者有一定比例的正常死亡率的，剔除正常死亡率之后，日本赠台AZ造成的非正常死亡恐怕是英国AZ的二十倍不止。

难怪美国FDA在极大的政治压力下，在巴尔的摩工厂库房扒拉几个月，对绝大多数库存仍是死活不肯放行。加拿大宁肯使用过期一个月的印度、欧洲产库存AZ,也要坚决作废巴尔的摩AZ。

也难怪日本办奥运会，那么缺疫苗，仍然不肯打这批3000万剂AZ，赠送给盟友。看来日本从731部队遗留下的研究精神，八十年过去了一点也没忘下。

拿活人做大规模实验

这副脸孔不是很好看

他们用自己的生命为其他民族证明病毒的可怕、平民的无助以及政府无能的恐怕后果！

个顶个能言善辩，舌灿莲花，临到大灾大难就只会躺平等死，当然都还有空闲、不忘打着吊针，以最怨毒的言语去攻击中国。

趋势已经建立起来了，下一波疫情不可避免

密切关注他们的重症和死亡病例

ACTIVE CASES：

Currently Infected Patients：606

in Mild Condition：580 (96%)

Serious or Critical: 26 (4%)

目前重症比例4%。

以色列已经授权隔离所有新冠密切接触者，无论他们是否完成疫苗接种。

这个信号对于寄托希望于完全恢复正常的欧美各国是当头一棒，基本上预示着依靠疫苗完全消灭新冠的希望破灭了。

Vaccinated Israelis may need to quarantine because of Delta variant

如果mRNA疫苗技术不成熟，那么美国投毒行为就过于冒失疯狂了，只有川普干的出来。

正好前面有一个女儿陪老人来打的，看起来岁数也不大，不到60.但是打针的医护特意提醒了高血压，她自己解释是当天没吃药就来了，血压明显偏高。医护就让她回去吃完药稳定了血压再来。

当天在现场还有一个细节，有一个第一针是在安徽打的，当时在安徽出差，正好被隔离了，第二针是给专门递到北京的，社区收到了后专门通知了来打。是不是因为需要同一个批次？没和那个哥们聊，所以只能揣测。但是不管怎么样，国家对待打疫苗这件事上还是很严谨的。

在雪球APP上讨论了下疫苗，说必复泰大概率不会被国内批准，被人私信“他不是一般散户，记住我啦，用IP地址查找我……”